BRISTOL-MYERS SQUIBB COMPANY for BRISTOL-MYERS SQUIBB COMPANY
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions H.R.7635, the 340B PATIENTS Act H.R.2163, to amend the Employee Retirement Income Security Act to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for a medication step therapy protocol, and for other purposes H.R.2071, to amend Part D of title XVII of the Social Security Act to require the secretary of Health and Human Services to negotiate covered Part D drug prices on behalf of Medicare beneficiaries - regarding all bio-pharmaceutical provisions
| Lobbyist | Covered position, as disclosed |
|---|---|
| THOMAS BRUNET | — |
| JOHN DEOUDES | — |
| KIRBY MILLER New | LA - U.S.Senateor RWicker (2020-2022); U.S.House Dep. CoS Rep. Trent Kelly (2019-2020); LD,LA,LC U.S.House Rep Rod Blum (2015-2019); U.S.House Staff Asst Rep. Stephen Fincher(2014-2015) |
| KATHRYN NOVARIA | — |
| LANE PENRY | — |
| PAUL ANTHONY WILLIAMS | — |
Taxation/Internal Revenue Code TAX
Proposed policies regarding corporate tax reform - regarding all bio-pharmaceutical related provisions OECD Implementation
| Lobbyist | Covered position, as disclosed |
|---|---|
| THOMAS BRUNET | — |
| JOHN DEOUDES | — |
| LANE PENRY | — |
Copyright/Patent/Trademark CPT
Intellectual Property Reform concerning bio-pharmaceutical industry
| Lobbyist | Covered position, as disclosed |
|---|---|
| THOMAS BRUNET | — |
| KIRBY MILLER New | LA - U.S.Senateor RWicker (2020-2022); U.S.House Dep. CoS Rep. Trent Kelly (2019-2020); LD,LA,LC U.S.House Rep Rod Blum (2015-2019); U.S.House Staff Asst Rep. Stephen Fincher(2014-2015) |
| LANE PENRY | — |
| PAUL ANTHONY WILLIAMS | — |
Pharmacy PHA
H.R.830, HELP Copays Act of 2023 S.127, Pharmacy Benefit Manager Transparency Act of 2023 H.R.3283, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act H.R.5378, Lower Costs, More Transparency Act S.2973, Modernizing and Ensuring PBM Accountability Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| THOMAS BRUNET | — |
| JOHN DEOUDES | — |
| SOFIA FOX New | LC - U.S. House office of Rep Travis Childers (2009-1010) |
| KIRBY MILLER New | LA - U.S.Senateor RWicker (2020-2022); U.S.House Dep. CoS Rep. Trent Kelly (2019-2020); LD,LA,LC U.S.House Rep Rod Blum (2015-2019); U.S.House Staff Asst Rep. Stephen Fincher(2014-2015) |
| KATHRYN NOVARIA | — |
| LANE PENRY | — |
Health Issues HCR
Discussions regarding promoting health equity International Reference Pricing/Most Favored Nation, regarding all bio-pharmaceutical issues Ensuring Pathways to Innovation Cures (EPIC) Act ORPHAN Act Implementation of Inflation Reduction Act of 2022 MINI Act H.R. 8412, Clinical Trial Modernization Act S.652/H.R.2630, Safe Step Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| THOMAS BRUNET | — |
| JOHN DEOUDES | — |
| STEPHANIE A. DYSON | — |
| SOFIA FOX New | LC - U.S. House office of Rep Travis Childers (2009-1010) |
| KATHRYN NOVARIA | — |
| LANE PENRY | — |
| CAROLINE TUCKER | — |
| PAUL ANTHONY WILLIAMS | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.